CABA's logo.
Ticker Symbol: CABA

Cabaletta Bio Inc

$11.98 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001759138

Company Profile

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
CEO: N/A
Tags:
  • Health Technology
  • Biotechnology

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $13.42
Change: $0.21 ( 1.63%)
Days Range: $12.68 - $13.99
Beta: 1.09
52wk. High: $19.34
52wk. Low: $1.55
Ytd. Change 44.38%
50 Day Moving Average: $15.16
200 Day Moving Average: $12.58
Shares Outstanding: 39805032

Valuation

Market Cap: 53.4B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A